CN Patent

CN114269376A — 用抗pd-l1抗体治疗癌症的方法

Assigned to F Hoffmann La Roche AG · Expires 2022-04-01 · 4y expired

What this patent protects

本公开涉及与通过向患者施用抗PD‑L1抗体(例如，阿特珠单抗)来治疗癌症相关的方法、用途和试剂盒。在一些实施方案中，以每2周840mg或每4周1680mg将所述抗PD‑L1抗体施用两个或更多个周期。

USPTO Abstract

本公开涉及与通过向患者施用抗PD‑L1抗体(例如，阿特珠单抗)来治疗癌症相关的方法、用途和试剂盒。在一些实施方案中，以每2周840mg或每4周1680mg将所述抗PD‑L1抗体施用两个或更多个周期。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN114269376A
Jurisdiction: CN
Classification: —
Expires: 2022-04-01
Drug substance claim: No
Drug product claim: No
Assignee: F Hoffmann La Roche AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.